Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of AgeMirna Chehade, Jennifer Maloney, Naimish Patel et al.|New England Journal of Medicine|2024Cited by 107
Dupilumab Improves Histologic And Endoscopic Outcomes In Children Aged 1 To <12 Years With Eosinophilic Esophagitis (EoE): 52-Week Results From The Phase 3 EoE KIDS TrialMirna Chehade, Arsalan Shabbir, Jennifer D. Hamilton et al.|Journal of Allergy and Clinical Immunology|2024Cited by 7